Skip to main content

Advertisement

Log in

MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell lung cancer

  • Original Article
  • Published:
Tumor Biology

Abstract

Lung cancer remains a leading cause of cancer-associated mortality worldwide, and non-small lung cancer (NSCLC) is responsible for over 80 % of lung cancer-related deaths. Identifying novel molecular biomarker that can inhibit the progression of lung cancer will facilitate the development of new treatment strategies. Herein, we demonstrated that miR-541-3p is a tumor-suppressor microRNA (miRNA) in NSCLC progression. We found that expression of miR-541-3p was decreased obviously in NSCLC tissues and plasma. Down-regulation of miR-541-3p was associated with TNM stage and postoperative survival. Overexpression of miR-541-3p inhibited the growth and metastasis of NSCLC cells. The TGIF2 was a direct target of miR-541-3p and promoted the growth and metastasis of NSCLC cells. Further study showed that TGIF2 could reverse the inhibitory effect of miR-541-3p on growth and metastasis of NSCLC cells. Taken together, our data highlight the pivotal role of miR-541-3p in the progression of NSCLC. Thus, miR-541-3p may be a potential prognostic marker and of treatment relevance for NSCLC progression intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016. doi:10.3322/caac.21338.

    Google Scholar 

  3. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44. doi:10.1200/JCO.2005.04.4859.

    Article  PubMed  Google Scholar 

  4. Song YJ, Wang LX, Hong YQ, Lu ZH, Tong Q, Fang XZ, et al. Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients. Tumour Biol. 2015. doi:10.1007/s13277-015-4397-8.

    Google Scholar 

  5. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–79. doi:10.1146/annurev.med.59.053006.104707.

    Article  CAS  PubMed  Google Scholar 

  6. Fang L, Cai J, Chen B, Wu S, Li R, Xu X, et al. Aberrantly expressed miR-582-3p maintains lung cancer stem cell-like traits by activating Wnt/beta-catenin signalling. Nat Commun. 2015;6:8640. doi:10.1038/ncomms9640.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Shi L, Zhang B, Sun X, Lu S, Liu Z, Liu Y, et al. MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1. Br J Cancer. 2014;111(12):2316–27. doi:10.1038/bjc.2014.580.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sun Y, Chen C, Zhang P, Xie H, Hou L, Hui Z, et al. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway. Sci Rep. 2014;4:6527. doi:10.1038/srep06527.

    Article  CAS  PubMed  Google Scholar 

  9. Yang L, Yang J, Li J, Shen X, Le Y, Zhou C, et al. MircoRNA-33a inhibits epithelial-to-mesenchymal transition and metastasis and could be a prognostic marker in non-small cell lung cancer. Sci Rep. 2015;5:13677. doi:10.1038/srep13677.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Leivonen SK, Sahlberg KK, Makela R, Due EU, Kallioniemi O, Borresen-Dale AL, et al. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol. 2014;8(1):93–104. doi:10.1016/j.molonc.2013.10.001.

    Article  CAS  PubMed  Google Scholar 

  11. Hrdlickova R, Nehyba J, Bargmann W, Bose Jr HR. Multiple tumor suppressor microRNAs regulate telomerase and TCF7, an important transcriptional regulator of the Wnt pathway. PLoS One. 2014;9(2):e86990. doi:10.1371/journal.pone.0086990.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Imoto I, Pimkhaokham A, Watanabe T, Saito-Ohara F, Soeda E, Inazawa J. Amplification and overexpression of TGIF2, a novel homeobox gene of the TALE superclass, in ovarian cancer cell lines. Biochem Biophys Res Commun. 2000;276(1):264–70. doi:10.1006/bbrc.2000.3449.

    Article  CAS  PubMed  Google Scholar 

  13. Wang Y, Wang CM, Jiang ZZ, Yu XJ, Fan CG, Xu FF, et al. MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Oncol Lett. 2015;10(5):3095–102. doi:10.3892/ol.2015.3649.

    PubMed  PubMed Central  Google Scholar 

  14. Tian Y, Wei W, Li L, Yang R. Down-regulation of miR-148a promotes metastasis by DNA methylation and is associated with prognosis of skin cancer by targeting TGIF2. Med Sci Monit. 2015;21:3798–805.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Hu Y, Pu Q, Cui B, Lin J. MicroRNA-34a inhibits tumor invasion and metastasis in gastric cancer by targeting TGIF2. Int J Clin Exp Pathol. 2015;8(8):8921–8.

    PubMed  PubMed Central  Google Scholar 

  16. Deng Q, He B, Gao T, Pan Y, Sun H, Xu Y, et al. Up-regulation of 91H promotes tumor metastasis and predicts poor prognosis for patients with colorectal cancer. PLoS One. 2014;9(7):e103022. doi:10.1371/journal.pone.0103022.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sun H, Pan Y, He B, Deng Q, Li R, Xu Y, et al. Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the insulin-like growth factor 2 imprinting. Int J Oncol. 2015;46(4):1759–67. doi:10.3892/ijo.2015.2852.

    PubMed  Google Scholar 

  18. Yabushita S, Fukamachi K, Tanaka H, Sumida K, Deguchi Y, Sukata T, et al. Circulating microRNAs in serum of human K-Ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Pancreas. 2012;41(7):1013–8. doi:10.1097/MPA.0b013e31824ac3a5.

    Article  CAS  PubMed  Google Scholar 

  19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33. doi:10.1016/j.cell.2009.01.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Koso H, Tsuhako A, Lyons E, Ward JM, Rust AG, Adams DJ, et al. Identification of FoxR2 as an oncogene in medulloblastoma. Cancer Res. 2014;74(8):2351–61. doi:10.1158/0008-5472.CAN-13-1523.

    Article  CAS  PubMed  Google Scholar 

  21. Lee J, Warnken U, Schnolzer M, Gebert J, Kopitz J. A new method for detection of tumor driver-dependent changes of protein sialylation in a colon cancer cell line reveals nectin-3 as TGFBR2 target. Protein Sci. 2015;24(10):1686–94. doi:10.1002/pro.2741.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Quiles F, Menendez M, Tornero E, Del Valle J, Teule A, Palanca S, et al. Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA. Breast Cancer Res Treat. 2016;155(2):253–60. doi:10.1007/s10549-015-3676-9.

    Article  CAS  PubMed  Google Scholar 

  23. Lips EH, van Eijk R, de Graaf EJ, Oosting J, de Miranda NF, Karsten T, et al. Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis. BMC Cancer. 2008;8:314. doi:10.1186/1471-2407-8-314.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, et al. MiR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and TGIF2. Nature. 2014;512(7515):431–5. doi:10.1038/nature13375.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rong-Yu Liu.

Ethics declarations

Authors’ contributions

YJL and RYL conceived and designed the experiments. YJL, KH, and YW performed the experiments. YJL analyzed the data. YJL and KH contributed reagents/materials/analysis tools. YJL and RYL wrote the manuscript.

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, YJ., Liu, RY., Hu, K. et al. MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell lung cancer. Tumor Biol. 37, 12685–12695 (2016). https://doi.org/10.1007/s13277-016-5241-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-5241-5

Keywords

Navigation